Abstract:Age-dependent neurodegenerative diseases progressively form aggregates containing both shared components (e.g., TDP-43, phosphorylated tau) and proteins specific to each disease. We investigated whether diverse neuropathies might have additional aggregation-prone proteins in common, discoverable by proteomics. Caenorhabditis elegans expressing unc-54p/Q40::YFP, a model of polyglutamine array diseases such as Huntington's, accrues aggregates in muscle 2-6days posthatch. These foci, isolated on antibody-coupled magnetic beads, were characterized by high-resolution mass spectrometry. Three Q40::YFP-associated proteins were inferred to promote aggregation and cytotoxicity, traits reduced or delayed by their RNA interference knockdown. These RNAi treatments also retarded aggregation/cytotoxicity in Alzheimer's disease models, nematodes with muscle or pan-neuronal A(1-42) expression and behavioral phenotypes. The most abundant aggregated proteins are glutamine/asparagine-rich, favoring hydrophobic interactions with other random-coil domains. A particularly potent modulator of aggregation, CRAM-1/HYPK, contributed <1% of protein aggregate peptides, yet its knockdown reduced Q40::YFP aggregates 7286% (P<10(-6)). In worms expressing A(1-42), knockdown of cram-1 reduced -amyloid 60% (P<0.002) and slowed age-dependent paralysis >30% (P<10(-6)). In wild-type worms, cram-1 knockdown reduced aggregation and extended lifespan, but impaired early reproduction. Protection against seeded aggregates requires proteasome function, implying that normal CRAM-1 levels promote aggregation by interfering with proteasomal degradation of misfolded proteins. Molecular dynamic modeling predicts spontaneous and stable interactions of CRAM-1 (or human orthologs) with ubiquitin, and we verified that CRAM-1 reduces degradation of a tagged-ubiquitin reporter. We propose that CRAM-1 exemplifies a class of primitive chaperones that are initially protective and highly beneficial for early reproduction, but ultimately impair aggregate clearance and limit longevity.

Intracellular Degradation of Misfolded Proteins in Polyglutamine Neurodegenerative Diseases

Polyglutamine Protein Trafficking and Neurodegeneration

Autophagy and Polyglutamine Disease

Current Understanding on the Pathogenesis of Polyglutamine Diseases

Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity

Nuclear Accumulation of Polyglutamine Disease Proteins and Neuropathology

Endosome mediated nucleocytoplasmic trafficking and endomembrane allocation is crucial to polyglutamine toxicity

Transcriptional Dysregulation: A Therapeutic Target for Polyglutamine Diseases

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Aggregation of Polyglutamine-Expanded Ataxin-3 Sequesters Its Specific Interacting Partners into Inclusions: Implication in a Loss-of-function Pathology

Altered Metabolic Signaling and Potential Therapies in Polyglutamine Diseases

Extracellular Vesicles Physiological Role and the Particular Case of Disease-Spreading Mechanisms in Polyglutamine Diseases

Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics

Polyglutamine Expansion Alters the Dynamics and Molecular Architecture of Aggregates in Dentatorubropallidoluysian Atrophy

Misfolded Protein Aggregation and Altered Cellular Pathways in Neurodegenerative Diseases

Aberrant Stress Granule Dynamics and Aggrephagy in ALS Pathogenesis

Proteins in Aggregates Functionally Impact Multiple Neurodegenerative Disease Models by Forming Proteasome-Blocking Complexes

The Expanding Clinical Universe of Polyglutamine Disease.

Proteasomal Dysfunction in Aging and Huntington Disease

Autophagy in Axonal and Dendritic Degeneration

The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans